Increasing unusual put option volume: WEN EVGO MQ MAPS SNDL AZN SFT BLNK
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
AstraZeneca (AZN) Has Supplied Two Billion Doses of COVID-19 Vaccine in 11 Months
November 16, 2021 6:00 AM ESTAstraZeneca (NASDAQ: AZN) and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the last 11 months.
Approximately two-thirds of these have gone to low- and lower-middle-income countries, including more than 175 million doses delivered to 130 countries through the COVAX Facility.
This milestone comes just over 18 months after AstraZeneca and Oxford University formed their landmark partnership for the global development and distribution... More
AstraZeneca (AZN) Reports Positive Phase IIa Results from the EPICCURE Trial
November 15, 2021 8:24 AM ESTAstraZeneca (NASDAQ: AZN) announces positive Phase IIa results from the EPICCURE trial, demonstrating that AZD8601 met the primary endpoint of safety and tolerability in patients with heart failure.
In the trial, researchers injected mRNA encoding vascular endothelial growth factor (VEGF-A) known as AZD8601 directly into the myocardium of patients undergoing elective coronary artery bypass surgery (CABG) surgery. AZD8601 is being co-developed with Moderna.
In the study... More

